• New trial will assess psilocybin for depression treatment

    9 days ago - By Healio

    Pacific Neuroscience Institute announced the start of a new clinical trial to assess the safety and efficacy of psilocybin to treat major depressive disorder and has begun participant enrollment, according to a company release.
    The trial will be a continuation of the PSIL201 study, begun as a phase 2, randomized, double-blinded, placebo-controlled, multi-site study sponsored by Usona Institute, which began in 2019.
    A total of 100 otherwise healthy participants diagnosed with MDD will be randomly assigned to receive either a single dose of psilocybin in capsule form or placebo.
    Effectiveness of
    Read more ...